Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Lynn Heasley to Cell Line, Tumor

This is a "connection" page, showing publications Lynn Heasley has written about Cell Line, Tumor.

 
Connection Strength
 
 
 
1.324
 
  1. Hinz TK, Kalkur R, Rabinovitch J, Hinkle W, Heasley LE. TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin. Mol Pharmacol. 2021 08; 100(2):144-154.
    View in: PubMed
    Score: 0.118
  2. Korpela SP, Hinz TK, Oweida A, Kim J, Calhoun J, Ferris R, Nemenoff RA, Karam SD, Clambey ET, Heasley LE. Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response. J Transl Med. 2021 01 23; 19(1):43.
    View in: PubMed
    Score: 0.115
  3. Hinz TK, Kleczko EK, Singleton KR, Calhoun J, Marek LA, Kim J, Tan AC, Heasley LE. Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines. Mol Pharmacol. 2019 12; 96(6):862-870.
    View in: PubMed
    Score: 0.105
  4. Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC, Heasley LE. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. Cancer Res. 2015 Oct 15; 75(20):4398-406.
    View in: PubMed
    Score: 0.079
  5. Kleczko EK, Kim J, Keysar SB, Heasley LR, Eagles JR, Simon M, Marshall ME, Singleton KR, Jimeno A, Tan AC, Heasley LE. An Inducible TGF-?2-TGF?R Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases. PLoS One. 2015; 10(5):e0123600.
    View in: PubMed
    Score: 0.078
  6. Marek LA, Hinz TK, von M?ssenhausen A, Olszewski KA, Kleczko EK, Boehm D, Weiser-Evans MC, Nemenoff RA, Hoffmann H, Warth A, Gozgit JM, Perner S, Heasley LE. Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma. Mol Cancer Res. 2014 Oct; 12(10):1460-9.
    View in: PubMed
    Score: 0.073
  7. Singleton KR, Kim J, Hinz TK, Marek LA, Cas?s-Selves M, Hatheway C, Tan AC, DeGregori J, Heasley LE. A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. Mol Pharmacol. 2013 Apr; 83(4):882-93.
    View in: PubMed
    Score: 0.066
  8. Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, Marek L, Frederick BA, Raben D, Heasley LE. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res. 2011 Aug 01; 17(15):5016-25.
    View in: PubMed
    Score: 0.059
  9. Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, Hercule P, Helfrich BA, Doebele RC, Heasley LE. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS One. 2010 Nov 29; 5(11):e14117.
    View in: PubMed
    Score: 0.057
  10. Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich BA, Bunn PA, Heasley LE. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol. 2009 Jan; 75(1):196-207.
    View in: PubMed
    Score: 0.049
  11. Heasley LE, Winn RA. Analysis of Wnt7a-stimulated JNK activity and cJun phosphorylation in non-small cell lung cancer cells. Methods Mol Biol. 2008; 468:187-96.
    View in: PubMed
    Score: 0.047
  12. Winn RA, Marek L, Han SY, Rodriguez K, Rodriguez N, Hammond M, Van Scoyk M, Acosta H, Mirus J, Barry N, Bren-Mattison Y, Van Raay TJ, Nemenoff RA, Heasley LE. Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J Biol Chem. 2005 May 20; 280(20):19625-34.
    View in: PubMed
    Score: 0.038
  13. Winn RA, Heasley LE. Gamma-catenin expression is reduced or absent in a subset of human non-small cell lung cancers, and its re-expression inhibits cell growth. Chest. 2004 May; 125(5 Suppl):122S-3S.
    View in: PubMed
    Score: 0.036
  14. Oweida A, Hararah MK, Phan A, Binder D, Bhatia S, Lennon S, Bukkapatnam S, Van Court B, Uyanga N, Darragh L, Kim HM, Raben D, Tan AC, Heasley L, Clambey E, Nemenoff R, Karam SD. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. Clin Cancer Res. 2018 11 01; 24(21):5368-5380.
    View in: PubMed
    Score: 0.024
  15. Bhatia S, Griego A, Lennon S, Oweida A, Sharma J, Rohmer C, Uyanga N, Bukkapatnam S, Van Court B, Raben D, Young C, Heasley L, Karam SD. Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor. Mol Cancer Ther. 2018 09; 17(9):2049-2059.
    View in: PubMed
    Score: 0.024
  16. Bhatia S, Sharma J, Bukkapatnam S, Oweida A, Lennon S, Phan A, Milner D, Uyanga N, Jimeno A, Raben D, Somerset H, Heasley L, Karam SD. Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers. Clin Cancer Res. 2018 09 15; 24(18):4539-4550.
    View in: PubMed
    Score: 0.024
  17. Li HY, McSharry M, Bullock B, Nguyen TT, Kwak J, Poczobutt JM, Sippel TR, Heasley LE, Weiser-Evans MC, Clambey ET, Nemenoff RA. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. Cancer Immunol Res. 2017 09; 5(9):767-777.
    View in: PubMed
    Score: 0.023
  18. Vaishnavi A, Schubert L, Rix U, Marek LA, Le AT, Keysar SB, Glogowska MJ, Smith MA, Kako S, Sumi NJ, Davies KD, Ware KE, Varella-Garcia M, Haura EB, Jimeno A, Heasley LE, Aisner DL, Doebele RC. EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res. 2017 07 01; 77(13):3551-3563.
    View in: PubMed
    Score: 0.022
  19. Suda K, Rozeboom L, Rivard CJ, Yu H, Ellison K, Melnick MAC, Hinz TK, Chan D, Heasley LE, Politi K, Mitsudomi T, Hirsch FR. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer. 2017 07; 109:1-8.
    View in: PubMed
    Score: 0.022
  20. Ohm AM, Tan AC, Heasley LE, Reyland ME. Co-dependency of PKCd and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer. Oncogene. 2017 07 27; 36(30):4370-4378.
    View in: PubMed
    Score: 0.022
  21. Nakachi I, Helfrich BA, Spillman MA, Mickler EA, Olson CJ, Rice JL, Coldren CD, Heasley LE, Geraci MW, Stearman RS. PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines. Clin Transl Sci. 2016 12; 9(6):293-301.
    View in: PubMed
    Score: 0.021
  22. von M?ssenhausen A, Deng M, Billig H, Queisser A, Vogel W, Kristiansen G, Schr?ck A, Bootz F, G?ke F, Franzen A, Heasley L, Kirfel J, Br?gelmann J, Perner S. Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma. Target Oncol. 2016 10; 11(5):631-642.
    View in: PubMed
    Score: 0.021
  23. von M?ssenhausen A, Sanders C, Thewes B, Deng M, Queisser A, Vogel W, Kristiansen G, Duensing S, Schr?ck A, Bootz F, Brossart P, Kirfel J, Heasley L, Br?gelmann J, Perner S. MERTK as a novel therapeutic target in head and neck cancer. Oncotarget. 2016 May 31; 7(22):32678-94.
    View in: PubMed
    Score: 0.021
  24. Ryall KA, Kim J, Klauck PJ, Shin J, Yoo M, Ionkina A, Pitts TM, Tentler JJ, Diamond JR, Eckhardt SG, Heasley LE, Kang J, Tan AC. An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. BMC Genomics. 2015; 16 Suppl 12:S2.
    View in: PubMed
    Score: 0.020
  25. G?ke F, Franzen A, Hinz TK, Marek LA, Yoon P, Sharma R, Bode M, von Maessenhausen A, Lankat-Buttgereit B, G?ke A, Golletz C, Kirsten R, Boehm D, Vogel W, Kleczko EK, Eagles JR, Hirsch FR, Van Bremen T, Bootz F, Schroeck A, Kim J, Tan AC, Jimeno A, Heasley LE, Perner S. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. Clin Cancer Res. 2015 Oct 01; 21(19):4356-64.
    View in: PubMed
    Score: 0.019
  26. Sena JA, Wang L, Heasley LE, Hu CJ. Hypoxia regulates alternative splicing of HIF and non-HIF target genes. Mol Cancer Res. 2014 Sep; 12(9):1233-43.
    View in: PubMed
    Score: 0.018
  27. Kim J, Vasu VT, Mishra R, Singleton KR, Yoo M, Leach SM, Farias-Hesson E, Mason RJ, Kang J, Ramamoorthy P, Kern JA, Heasley LE, Finigan JH, Tan AC. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy. Bioinformatics. 2014 Sep 01; 30(17):2393-8.
    View in: PubMed
    Score: 0.018
  28. Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One. 2013; 8(12):e82236.
    View in: PubMed
    Score: 0.018
  29. Avasarala S, Bikkavilli RK, Van Scoyk M, Zhang W, Lapite A, Hostetter L, Byers JT, Heasley LE, Sohn JW, Winn RA. Heterotrimeric G-protein, Ga16, is a critical downstream effector of non-canonical Wnt signaling and a potent inhibitor of transformed cell growth in non small cell lung cancer. PLoS One. 2013; 8(10):e76895.
    View in: PubMed
    Score: 0.017
  30. G?ke F, G?ke A, von M?ssenhausen A, Franzen A, Sharma R, Kirsten R, B?hm D, Kristiansen G, Stenzinger A, Wynes M, Hirsch FR, Weichert W, Heasley L, Buettner R, Perner S. Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer. Digestion. 2013; 88(3):172-81.
    View in: PubMed
    Score: 0.017
  31. Symonds JM, Ohm AM, Carter CJ, Heasley LE, Boyle TA, Franklin WA, Reyland ME. Protein kinase C d is a downstream effector of oncogenic K-ras in lung tumors. Cancer Res. 2011 Mar 15; 71(6):2087-97.
    View in: PubMed
    Score: 0.014
  32. Wang XQ, Li H, Van Putten V, Winn RA, Heasley LE, Nemenoff RA. Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9. Mol Biol Cell. 2009 Feb; 20(3):791-800.
    View in: PubMed
    Score: 0.012
  33. Bren-Mattison Y, Meyer AM, Van Putten V, Li H, Kuhn K, Stearman R, Weiser-Evans M, Winn RA, Heasley LE, Nemenoff RA. Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol. 2008 Mar; 73(3):709-17.
    View in: PubMed
    Score: 0.012
  34. Winn RA, Van Scoyk M, Hammond M, Rodriguez K, Crossno JT, Heasley LE, Nemenoff RA. Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma. J Biol Chem. 2006 Sep 15; 281(37):26943-50.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)